Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 12 citing articles:

Precision Therapeutics in Lennox–Gastaut Syndrome: Targeting Molecular Pathophysiology in a Developmental and Epileptic Encephalopathy
Debopam Samanta
Children (2025) Vol. 12, Iss. 4, pp. 481-481
Open Access | Times Cited: 1
Women With Genetic Epilepsies
Paula Marques, Nagham Kaka, Quratulain Zulfiqar Ali, et al.
Neurology Genetics (2025) Vol. 11, Iss. 1
Open Access
Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition
Hongxia Jia, T. Eric Ballard, Liming Zhang, et al.
Clinical Pharmacology in Drug Development (2025)
Open Access
Efficacy, safety, and tolerability of soticlestat (TAK-935) as adjunctive therapy in pediatric patients with dravet syndrome and Lennox–Gastaut syndrome: a meta-analysis of 3 randomized controlled trials
Lanlan Zhang, Jean Nana, Chengzhong Wang
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Current and Emerging Precision Therapies for Developmental and Epileptic Encephalopathies
Debopam Samanta, Sonal Bhatia, Senyene E. Hunter, et al.
Pediatric Neurology (2025) Vol. 168, pp. 67-81
Closed Access
Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies
Wei Yin, Axel Facius, Mahnaz Asgharnejad, et al.
Clinical and Translational Science (2024) Vol. 17, Iss. 3
Open Access | Times Cited: 3
Unbiased insights into the multiplicity of the CYP46A1 brain effects in 5XFAD mice treated with low dose-efavirenz
Natalia Mast, Makaya Butts, Irina A. Pikuleva
Journal of Lipid Research (2024) Vol. 65, Iss. 6, pp. 100555-100555
Open Access | Times Cited: 3
Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function
Wei Yin, P. P. Mitra, Veronique Copalu, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 2
7,8-Dihydroxy Efavirenz Is Not as Effective in CYP46A1 Activation In Vivo as Efavirenz or Its 8,14-Dihydroxy Metabolite
Natalia Mast, Yong Li, Irina A. Pikuleva
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 2242-2242
Open Access
Odkrywanie złożoności encefalopatii rozwojowej i padaczkowej związanej z genem CDKL5 — czy na horyzoncie pojawiła się nowa terapia?
Klaudia Bartoszewicz, Barbara Steinborn
Child Neurology (2024) Vol. 33, Iss. 61, pp. 35-40
Open Access
The small steps that lead to big impact: translating therapeutics from idea to reality for the CDKL5 deficiency disorder community
Amanda Jaksha, M. P. Bishop, Karen Utley, et al.
Therapeutic Advances in Rare Disease (2024) Vol. 5
Open Access
Concentration‐QTc analysis of soticlestat in healthy adults: An alternative to a thorough QT study
Wei Yin, Nobuhito Dote, Hiroyuki Fukase, et al.
British Journal of Clinical Pharmacology (2024)
Open Access
Page 1

Scroll to top